Excellus Prefers Its First Biosimilar

Excellus Prefers Its First Biosimilar

April 2nd, 2018 | Clinical ConnectionsNews

Starting February 1st for new prescriptions, Excellus will require the use of the biosimilar Inflectra (infliximab-dyyb) over Remicade (infliximab).

We recommend FDA’s biosimilar provider education and patient education materials.